Meeting
2022 ASCO Annual Meeting
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
Authors
Julien Edeline
Department of Medical Oncology, Eugene Marquis Center, Rennes, France
Julien Edeline , Philippe Merle , Weijia Fang , Eric Assenat , Hongming Pan , Lorenza Rimassa , Zhiwei Li , Jean-Frédéric Blanc , Chia-Jui Yen , Paul J. Ross , Sheng Hu , Tao Zhang , Albert Tran , Guoliang Shao , Mohamed Bouattour , Yajin Chen , John Wu , Vincent Li , Sandra Chica-Duque , Zhenggang Ren
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT03419897
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4072)
DOI
10.1200/JCO.2022.40.16_suppl.4072
Abstract #
4072
Poster Bd #
60
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208.
First Author: Julien Edeline
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Outcomes of patients with hepatocellular carcinoma (HCC) treated in the lenvatinib (LEN) and immunotherapy era (2018-2021) compared to the sorafenib (SOR) era (2008-2018).
First Author: Chloe Lim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of frontline systemic therapy for advanced hepatocellular carcinoma (aHCC): A network meta-analysis of landmark phase III trials.
First Author: Claudia A.M. Fulgenzi
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin